Investigational drug · Phase 3
licaminlimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye Disease (DED).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "licaminlimab"
First trial start
2026
Apr 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "licaminlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye Disease (DED)
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "licaminlimab" as an intervention, largest first.
- A Clinical Study Evaluating Licaminlimab for Dry Eye DiseasePivotal-lookingActive, not recruiting
OculisIndustry
NCT07548632 · 160 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2026
Drug: licaminlimab · For: Dry Eye Disease (DED)
Sites: Aliso Viejo, California; Garden Grove, California; Glendale, California · 14 sites in all
- Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye DiseasePivotal-lookingCompleted
OculisIndustry
NCT05896670 · 122 participants · Start Nov 29, 2023 · Primary completion Mar 27, 2024
Drug: licaminlimab · For: Dry Eye Disease
Sites: Newport Beach, California; Colorado Springs, Colorado; Shelby, North Carolina · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Quintessence of currently approved and upcoming treatments for dry eye disease.
Patil S, Sawale G, Ghuge S, et al. · Graefes Arch Clin Exp Ophthalmol 2025
- Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease: Retraction.
· Cornea 2024
- Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease [RETRACTED].
Donnenfeld E, Baudouin C, Galor A, et al. · Cornea 2024
- Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study.
Shettle L, McLaurin E, Martel J, et al. · Clin Ophthalmol 2022
- Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study.
Pasquali TA, Toyos MM, Abrams DB, et al. · Transl Vis Sci Technol 2022
Also in development for Dry Eye Disease (DED)
- DFL24498Phase 32 trials
Dompé Farmaceutici S.p.A · Dry Eye Disease (DED), Atopic Keratoconjunctivitis
- 0.25% RCI001RCI001Phase 22 trials
ORA, Inc. · Dry Eye Disease (DED), Dry Eye
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- BRM421Phase 21 trial
BRIM Biotechnology Inc. · Dry Eye Disease (DED), Keratoconjunctivitis Sicca
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.